Mazindol

Mazindol is a tricyclic anorexigenic agent approved for short-term obesity treatment and off-label narcolepsy management. Unlike amphetamines, it produces primarily dysphoric rather than euphoric effects, reducing abuse potential. Its dual mechanism targeting both monoamine reuptake and orexin-2 receptors makes it unique among stimulants. Common side effects include insomnia, dry mouth, anxiety, increased heart rate, and restlessness. Use with extreme caution in individuals with cardiovascular disease, hypertension, hyperthyroidism, or glaucoma.

Also known as: Sanorex, Mazanor, Teronac, Terenac, Dimagrir, AN-448, 42-548

Classification

Psychoactive: Stimulant
Tag: Appetite-suppressant
Tag: Eugeroic
Tag: Imidazoisoindole
Tag: Pharmaceutical
Tag: Tricyclic compound

Effects

Increased Alertness
Restlessness
Insomnia
Dry Mouth
Increased Heart Rate
Loss Of Appetite
Wakefulness
Anxiety
Focus Enhancement
Dysphoria
Motivation Enhancement
Euphoria
Appetite Suppression
Light Sensitivity
Dehydration
Photophobia
Spontaneous Physical Sensations
Increased Libido

Routes of Administration

Oral

Dosage

Threshold: 0.5 mg
Light: 0.5-1 mg
Common: 1-2 mg
Strong: 2-3 mg
Heavy: 3+ mg

Duration

Onset: 0.5-1 h
Comeup: 0.5-1.5 h
Peak: 2-4 h
Offset: 4-8 h
After Effects: 24 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu